Back to search

Article

Cost-Effectiveness Analysis of Dasatinib versus Imatinib in Pediatric Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia Patients in China

2022-05-09

Abstract excerpt

<h4>Background: </h4> Tyrosine kinase inhibitors (TKI) are recommended for pediatric Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL), and the one commonly used in China is imatinib. However, it's worth noting that clinical needs could not be met gradually with the increasing resistance of imatinib. Dasatinib, the second-generation TKI, has been proved by Food and Drug Administration because of the bet...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dc33123a-2c5c-57ec-b934-abb82e611ae5
DOI
10.21203/rs.3.rs-1618875/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cost-Effectiveness Analysis of Dasatinib versus Imatinib in Pediatric Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia Patients in ChinaDOI 10.21203/rs.3.rs-1618875/v1
The Economic Burden of Illness in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients from a Commercial and Medicaid Insurance PerspectiveSemantic proximity
Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.Semantic proximity
Dasatinib treatment for Philadelphia chromosome‐positive leukemiasSemantic proximity
A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood–brain Barrier in the Treatment of Patients With Philadelphia Chromosome–positive Acute Lymphoblastic LeukemiaSemantic proximity
Costs Associated with Adverse Events from Remission Induction for Children with Acute Lymphoblastic Leukemia (ALL)Semantic proximity
Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing ModelsSemantic proximity
Cost-Effectiveness of Sacituzumab Tirumotecan vs Chemotherapy for EGFR- TKI–Resistant NSCLC: Evidence to Inform Drug Pricing in the U.S. and ChinaSemantic proximity
Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With a BRAF V600E Mutation Low-Grade Glioma in England and Wales.Semantic proximity
Cost-effectiveness Analysis of Rituximab Associated With Fludarabine and Cyclophosphamide (R-FC) for the First-line Treatment of Chronic Lymphocytic Leukemia Under the Brazilian Public Health System (SUS).Semantic proximity
Cost-effectiveness of anti-CD20 monoclonal antibody associated with fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia in the Brazilian public health system (SUS)Semantic proximity
Dasatinib-induced pulmonary arterial hypertension in pediatric acute lymphoblastic leukemia with Philadelphia chromosome: A report of two casesSemantic proximity
Ibrutinib versus bendamustine plus rituximab for first-line treatment of older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research studySemantic proximity
Select a neighboring publication to make it the new centre.